FOXP3 and non-small cell lung carcinoma: In patients with NSCLC, shorter PFS was found in tumors with FoxP3 nuclear positivity (14.8 vs. 1.8 months, p = 0.003, HR 8.7, 95% CI 1.55–48.7) (Figure 2B).